HK-listed gold stocks jump as US economic fears boost bullion prices
SOUTH SAN FRANCISCO, Calif. - Senti Biosciences, Inc. (NASDAQ:SNTI), a clinical-stage biotech company trading near its InvestingPro Fair Value, announced today its participation in the Webull Corporate Connect Service (CCS) to enhance shareholder communication and transparency. The company, which is developing advanced cell and gene therapies for oncology using its proprietary Gene Circuit platform, aims to use the Webull CCS portal to keep shareholders and potential investors informed about corporate updates, including news, earnings, and product developments. With a market capitalization of approximately $76 million and a beta of 2.33, indicating higher volatility than the broader market, transparent communication remains crucial for investor confidence.
CEO and Co-Founder Timothy Lu emphasized the importance of transparent communication with shareholders as the company progresses clinically. He stated that the Webull platform complements their existing investor relations efforts and is expected to play a significant role in increasing market awareness and visibility among investors. According to InvestingPro data, the company maintains a strong current ratio of 4.49, indicating solid short-term liquidity, though analysts anticipate continued losses this year. InvestingPro subscribers have access to 8 additional key financial insights about SNTI.
Senti Bio’s lead candidate, SENTI-202, is currently in clinical development for the treatment of acute myeloid leukemia (AML). As of September 19, 2024, initial clinical data showed that two out of three patients achieved MRD-negative complete remissions, with durability extending beyond six months as of March 20, 2025. The company’s pipeline includes off-the-shelf CAR-NK cells with Gene Circuits designed to target various liquid and solid tumor indications.
Webull Financial, where Senti Bio’s information is now accessible, is a digital investment platform registered with the SEC and a member of both SIPC and FINRA. It serves millions of users worldwide, connecting investors with global companies.
The press release contains forward-looking statements, which are based on management’s current expectations and assumptions, but are subject to various risks and uncertainties. These statements include projections about the company’s clinical development success and shareholder value creation.
Investors can follow Senti Bio’s updates on the Webull platform by downloading the app and creating a free account. This move, as per the company’s statement, is part of its commitment to generating value for stakeholders in both the near and long term. The information in this article is based on a press release statement from Senti Biosciences.
In other recent news, Senti Biosciences, Inc. announced several key developments related to its leadership and financial structuring. The company appointed Jay Cross as its new Chief Financial Officer and Faraz Siddiqui as Senior Vice President of Technical Operations, with Cross’s role beginning in March 2025. Additionally, Senti Biosciences received stockholder approval for amendments to its 2022 Equity Incentive Plan, which includes an increase in shares available for equity awards. This plan aims to incentivize employees, consultants, and directors.
Feng Hsiung has been appointed to the Board of Directors, bringing extensive experience in investment and finance, and will also serve on the Audit Committee. Meanwhile, Brenda Cooperstone resigned from the Audit Committee but remains on the Board and Compensation Committee. The company also announced that stockholders approved the conversion of Series A convertible preferred stock and the exercise of warrants to purchase common stock, as part of its financial restructuring efforts.
Furthermore, Senti Biosciences granted stock options under its 2022 Inducement Equity Plan to new employees, including a significant allocation to Jay Cross. These developments reflect the company’s ongoing commitment to strengthening its leadership and financial strategies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.